The role of Aflibercept in the management of age-related macular degeneration

Muhammad Hassan, Rubbia Afridi, Mohammad Ali Sadiq, Mohamed Kamel Soliman, Aniruddha Agarwal, Yasir Jamal Sepah, Diana V. Do, Quan Dong Nguyen

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction: During the past decade, significant advances have occurred in the management of neovascular age-related macular degeneration (NV-AMD). The advent of anti-vascular endothelial growth factor (anti-VEGF) therapy has shifted the treatment goal of NV-AMD from merely salvaging vision to improving visual acuity and maintaining a good quality of life. Aflibercept (AFL) is a significant addition to the arsenal of anti-VEGF therapies against the NV-AMD. In the index review, pharmacology and efficacy of AFL has been reviewed.Areas Covered: An extensive literature search was performed to identify preclinical and clinical studies performed to illustrate the role of AFL in NV-AMD. Randomized clinical trials evaluating other anti-VEGF agents were also included for comparison. Additionally, studies where AFL was employed to treat anti-VEGF-resistant cases agents have been reviewed.Expert Opinion: AFL is an effective agent in the management of NV-AMD and its efficacy has been found to be comparable to ranibizumab (RBZ). Additionally, AFL is a good alternative agent in patients with NV-AMD resistant to RBZ and bevacizumab (BVZ), and can potentially lessen the treatment burden. As more research is conducted, the role of AFL in varying dosing regimens, as monotherapy and in combination with other agents, will become further defined.

Original languageEnglish (US)
Pages (from-to)699-709
Number of pages11
JournalExpert Opinion on Biological Therapy
Volume16
Issue number5
DOIs
StatePublished - May 3 2016

Fingerprint

Macular Degeneration
Vascular Endothelial Growth Factor A
Arsenals
Salvaging
Expert Testimony
Proxy
Therapeutics
aflibercept
Visual Acuity
Randomized Controlled Trials
Quality of Life
Pharmacology
Research

Keywords

  • Age-related macular degeneration
  • aflibercept
  • anchor
  • anti-vegf therapy
  • catt
  • clinicaltrials
  • degeneration
  • marina
  • vegf
  • view

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Hassan, M., Afridi, R., Sadiq, M. A., Soliman, M. K., Agarwal, A., Sepah, Y. J., ... Nguyen, Q. D. (2016). The role of Aflibercept in the management of age-related macular degeneration. Expert Opinion on Biological Therapy, 16(5), 699-709. https://doi.org/10.1517/14712598.2016.1167182

The role of Aflibercept in the management of age-related macular degeneration. / Hassan, Muhammad; Afridi, Rubbia; Sadiq, Mohammad Ali; Soliman, Mohamed Kamel; Agarwal, Aniruddha; Sepah, Yasir Jamal; Do, Diana V.; Nguyen, Quan Dong.

In: Expert Opinion on Biological Therapy, Vol. 16, No. 5, 03.05.2016, p. 699-709.

Research output: Contribution to journalArticle

Hassan, M, Afridi, R, Sadiq, MA, Soliman, MK, Agarwal, A, Sepah, YJ, Do, DV & Nguyen, QD 2016, 'The role of Aflibercept in the management of age-related macular degeneration', Expert Opinion on Biological Therapy, vol. 16, no. 5, pp. 699-709. https://doi.org/10.1517/14712598.2016.1167182
Hassan, Muhammad ; Afridi, Rubbia ; Sadiq, Mohammad Ali ; Soliman, Mohamed Kamel ; Agarwal, Aniruddha ; Sepah, Yasir Jamal ; Do, Diana V. ; Nguyen, Quan Dong. / The role of Aflibercept in the management of age-related macular degeneration. In: Expert Opinion on Biological Therapy. 2016 ; Vol. 16, No. 5. pp. 699-709.
@article{4c1cb1ee535c4710b4b2117c4602c328,
title = "The role of Aflibercept in the management of age-related macular degeneration",
abstract = "Introduction: During the past decade, significant advances have occurred in the management of neovascular age-related macular degeneration (NV-AMD). The advent of anti-vascular endothelial growth factor (anti-VEGF) therapy has shifted the treatment goal of NV-AMD from merely salvaging vision to improving visual acuity and maintaining a good quality of life. Aflibercept (AFL) is a significant addition to the arsenal of anti-VEGF therapies against the NV-AMD. In the index review, pharmacology and efficacy of AFL has been reviewed.Areas Covered: An extensive literature search was performed to identify preclinical and clinical studies performed to illustrate the role of AFL in NV-AMD. Randomized clinical trials evaluating other anti-VEGF agents were also included for comparison. Additionally, studies where AFL was employed to treat anti-VEGF-resistant cases agents have been reviewed.Expert Opinion: AFL is an effective agent in the management of NV-AMD and its efficacy has been found to be comparable to ranibizumab (RBZ). Additionally, AFL is a good alternative agent in patients with NV-AMD resistant to RBZ and bevacizumab (BVZ), and can potentially lessen the treatment burden. As more research is conducted, the role of AFL in varying dosing regimens, as monotherapy and in combination with other agents, will become further defined.",
keywords = "Age-related macular degeneration, aflibercept, anchor, anti-vegf therapy, catt, clinicaltrials, degeneration, marina, vegf, view",
author = "Muhammad Hassan and Rubbia Afridi and Sadiq, {Mohammad Ali} and Soliman, {Mohamed Kamel} and Aniruddha Agarwal and Sepah, {Yasir Jamal} and Do, {Diana V.} and Nguyen, {Quan Dong}",
year = "2016",
month = "5",
day = "3",
doi = "10.1517/14712598.2016.1167182",
language = "English (US)",
volume = "16",
pages = "699--709",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Elsevier BV",
number = "5",

}

TY - JOUR

T1 - The role of Aflibercept in the management of age-related macular degeneration

AU - Hassan, Muhammad

AU - Afridi, Rubbia

AU - Sadiq, Mohammad Ali

AU - Soliman, Mohamed Kamel

AU - Agarwal, Aniruddha

AU - Sepah, Yasir Jamal

AU - Do, Diana V.

AU - Nguyen, Quan Dong

PY - 2016/5/3

Y1 - 2016/5/3

N2 - Introduction: During the past decade, significant advances have occurred in the management of neovascular age-related macular degeneration (NV-AMD). The advent of anti-vascular endothelial growth factor (anti-VEGF) therapy has shifted the treatment goal of NV-AMD from merely salvaging vision to improving visual acuity and maintaining a good quality of life. Aflibercept (AFL) is a significant addition to the arsenal of anti-VEGF therapies against the NV-AMD. In the index review, pharmacology and efficacy of AFL has been reviewed.Areas Covered: An extensive literature search was performed to identify preclinical and clinical studies performed to illustrate the role of AFL in NV-AMD. Randomized clinical trials evaluating other anti-VEGF agents were also included for comparison. Additionally, studies where AFL was employed to treat anti-VEGF-resistant cases agents have been reviewed.Expert Opinion: AFL is an effective agent in the management of NV-AMD and its efficacy has been found to be comparable to ranibizumab (RBZ). Additionally, AFL is a good alternative agent in patients with NV-AMD resistant to RBZ and bevacizumab (BVZ), and can potentially lessen the treatment burden. As more research is conducted, the role of AFL in varying dosing regimens, as monotherapy and in combination with other agents, will become further defined.

AB - Introduction: During the past decade, significant advances have occurred in the management of neovascular age-related macular degeneration (NV-AMD). The advent of anti-vascular endothelial growth factor (anti-VEGF) therapy has shifted the treatment goal of NV-AMD from merely salvaging vision to improving visual acuity and maintaining a good quality of life. Aflibercept (AFL) is a significant addition to the arsenal of anti-VEGF therapies against the NV-AMD. In the index review, pharmacology and efficacy of AFL has been reviewed.Areas Covered: An extensive literature search was performed to identify preclinical and clinical studies performed to illustrate the role of AFL in NV-AMD. Randomized clinical trials evaluating other anti-VEGF agents were also included for comparison. Additionally, studies where AFL was employed to treat anti-VEGF-resistant cases agents have been reviewed.Expert Opinion: AFL is an effective agent in the management of NV-AMD and its efficacy has been found to be comparable to ranibizumab (RBZ). Additionally, AFL is a good alternative agent in patients with NV-AMD resistant to RBZ and bevacizumab (BVZ), and can potentially lessen the treatment burden. As more research is conducted, the role of AFL in varying dosing regimens, as monotherapy and in combination with other agents, will become further defined.

KW - Age-related macular degeneration

KW - aflibercept

KW - anchor

KW - anti-vegf therapy

KW - catt

KW - clinicaltrials

KW - degeneration

KW - marina

KW - vegf

KW - view

UR - http://www.scopus.com/inward/record.url?scp=84964388857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964388857&partnerID=8YFLogxK

U2 - 10.1517/14712598.2016.1167182

DO - 10.1517/14712598.2016.1167182

M3 - Article

C2 - 26982640

AN - SCOPUS:84964388857

VL - 16

SP - 699

EP - 709

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 5

ER -